Premium
Biosimilars in the EU: a new guide for health professionals
Author(s) -
Chaplin Steve
Publication year - 2017
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1617
Subject(s) - biosimilar , medicine , health professionals , european commission , agency (philosophy) , commission , alternative medicine , health care , family medicine , european union , international trade , law , pathology , finance , business , philosophy , epistemology , political science
With the number of biosimilar drugs being approved in the EU rising rapidly, the European Medicines Agency and the European Commission have jointly published a guide for healthcare professionals to provide reassurance on their safety and efficacy – but does it fall short of the rigorous analysis clinicians require?
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom